Amphastar Pharmaceuticals (AMPH) Earnings: What to Expect in Q4 Results

Amphastar Pharmaceuticals (AMPH) is set to release its fourth-quarter earnings results on February 27, 2025, after the market closes. Investors will be closely watching the company's performance, particularly after a strong year marked by revenue growth and earnings expansion. Here's what to expect from the upcoming earnings report and how the company's performance has influenced the stock's trajectory in recent quarters.



Q4 Earnings Expectations and Trends

Analysts expect Amphastar to report earnings per share (EPS) of $0.70 for the fourth quarter, compared to $0.87 in the same period last year. Revenue is expected to come in at $184.1 million, up from $135.02 million in Q4 2023. These estimates reflect a decrease in EPS and an increase in revenue compared to the previous year.

In the past four quarters, Amphastar has consistently beaten EPS estimates, with an average surprise of 11.11%. However, the company has missed revenue estimates in two of the past four quarters, with an average surprise of -1.83%. This trend suggests that while Amphastar has been able to exceed earnings expectations, its revenue performance has been more volatile.



Stock Performance and Earnings Impact

Amphastar's stock price has been influenced by its earnings performance in recent quarters. In Q1 2024, the company reported EPS of $1.15, beating estimates by 64.29%. The stock price increased by 0.521% on the release day and changed by -3.19% in the 4-day period before and after the release. In Q2 2024, Amphastar reported EPS of $1.14, beating estimates by 22.08%. The stock price increased by 13.29% on the release day and changed by 2.61% in the 4-day period before and after the release. In Q3 2024, the company missed earnings estimates, reporting EPS of $0.96 compared to the estimate of $0.99, resulting in a negative EPS surprise of 3.03%. The stock price decreased by 13.69% on the release day and changed by -5.58% in the 4-day period before and after the release.



Key Factors to Consider

Investors evaluating Amphastar's financial performance should consider several key factors, including the company's ability to navigate market challenges, maintain positive growth trends in core product areas, and manage competition effectively. Additionally, regulatory progress and the company's pipeline of promising products are crucial aspects to consider. By focusing on these factors, investors can gain a better understanding of Amphastar's financial performance and its potential for future growth.



In conclusion, Amphastar Pharmaceuticals is expected to report Q4 earnings on February 27, 2025, with analysts anticipating EPS of $0.70 and revenue of $184.1 million. The company's earnings trends in the past quarters have had a significant impact on the stock's performance, with positive EPS surprises generally leading to stock price increases. As investors await the upcoming earnings report, they should consider the company's ability to navigate market challenges, maintain growth trends, and manage competition effectively. By doing so, they can make more informed investment decisions based on the company's financial performance and potential for future growth.